Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 4/20 | 0.36 |
| ▸ | MMP9 | P14780 | 3/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | ACP3 | P15309 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.33 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787210 | 0.86 | CYP3A4 (0.39) | ADAM17MMP2MMP9MMP8CYP1A2 | |
| SCHEMBL6700587 | 0.85 | ADAM17 (0.43) | ADAM17PPARGPPARAMMP2CNR1 | |
| SCHEMBL11933939 | 0.84 | ADAM17 (0.48) | ADAM17PPARGPPARAMMP2MMP9 | |
| SCHEMBL10021371 | 0.81 | ALDH1A1 (0.43) | PPARGPPARAMMP2MMP9MMP8 | |
| SCHEMBL6842461 | 0.81 | MMP2 (0.40) | MMP2MMP9MMP8MMP3ACP3 | |
| SCHEMBL6839920 | 0.79 | MMP2 (0.36) | MMP2MMP9MMP8MMP3ACP3 | |
| SCHEMBL6790990 | 0.79 | MMP2 (0.41) | ADAM17MMP2MMP9MMP8MMP3 | |
| SCHEMBL6841039 | 0.79 | MMP2 (0.38) | MMP2MMP9MMP8MMP3ACP3 | |
| SCHEMBL6799515 | 0.77 | MMP2 (0.39) | MMP2MMP9MMP8MMP3ACP3 | |
| SCHEMBL8337447 | 0.77 | ADAMTS5 (0.41) | MMP2MMP9MMP8CYP1A2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370538-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074752-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110809-A1 | Metalloproteinase inhibitors | MMP9, MMP2, MMP3 | ADAM17 23/4885PPARG 3375/4885PPARA 4256/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | ADAM17 23/4885PPARG 2791/4885PPARA 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.